ArticlePoultry science2026
Dietary pyrroloquinoline quinone supplementation improves productive performance, immunity, and intestinal health in late-phase Jingfen No. 6 laying hens.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the effects of dietary pyrroloquinoline quinone (PQQ) on the productive performance, biochemical parameters, immune function, and intestinal health of laying hens during the late laying period. A total of 360 Jingfen No. 6 laying hens, aged 48 weeks, were randomly assigned to 5 dietary treatments (0, 0.5, 1.0, 2.0, and 4.0 mg/kg PQQ), with 6 replicates per treatment and 12 birds per replicate. Egg production performance, serum antibody titers, blood biochemical and immune indices, intestinal morphology, tight junction protein expression, and cecal microbiota and metabolite profiles were determined. The results showed that dietary supplementation with 0.5 and 1.0 mg/kg PQQ increased average daily egg mass and egg production rate (P < 0.01) and decreased the feed-to-egg ratio (P < 0.01). PQQ reduced serum malondialdehyde (MDA) and lactate dehydrogenase (LDH) levels (P < 0.05), alongside a significant increase in catalase (CAT) activity (P < 0.05). Antibody titers against H5, H7, and NDV were elevated in all PQQ-treated groups, with significant differences for H5 and NDV antibodies at 0.5 and 1.0 mg/kg groups (P < 0.05) and H7 antibodies in the 0.5 mg/kg group (P < 0.05). PQQ supplementation increased intestinal mucosal secretory immunoglobulin A (sIgA) content (P < 0.05), decreased serum interleukin-6 (IL-6) levels across all treatment doses (P < 0.01), and reduced IL-10 concentrations at 1.0 mg/kg (P < 0.05). Morphological analysis revealed that PQQ significantly increased jejunal villus height and the villus height-to-crypt depth ratio (P < 0.05 and P < 0.01), while upregulating mRNA expression of the tight junction proteins ZO-1 and Occludin (P < 0.05). PQQ significantly enhanced the relative abundance of beneficial bacterial genera including Prevotellaceae_Ga6A1_group, Lactobacillus, and Faecalibacterium. Metabolomic analysis revealed that PQQ predominantly upregulated intestinal organic acids including 6-(Pyridin-3-YL)hexanoic acid, DL-Valine-4-antipyrineamide, Eicosadienic acid, 2-methyl-hexadecanoic acid, and Penicilloic acid, while downregulating lipid metabolites including Triglycerides (TG), Phosphatidylglycerol (PG), and Phosphatidylcholine (PC). In conclusion, 0.5 to 1.0 mg/kg PQQ is optimal for enhancing productivity and antibody production in the late-phase laying hens through minimized oxidative damage, attenuated inflammation, and restructured intestinal microbiota and metabolic profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.